Skip to content
DataLookout
Menu

NCT06836609

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Primary and study completion pushed from May 15, 2027 to Aug 17, 2027
    • Final enrollment: 118 participants (planned 132)
    • Site details revised at 4 of 4 sites
  2. Minor Study sites: 3 to 4v7
  3. Notable Phase changed: Phase 1 → Phase 1/2v6
  4. Minor Study sites: 2 to 3v5
  5. Notable Eligibility criteria expanded, about 17 wordsv4 Show 4 more changesShow less
    • Enrollment target: 100 to 132
    • Primary and study completion dates: Mar 1, 2027 to May 15, 2027
    • Secondary endpoints revised (8)
    • Primary endpoints revised (2)
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 1 to 2v3
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria revised
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to 48 Weeks
Severity of TEAEs
Timeframe: Up to 48 Weeks

Secondary (8)

Change in liver fat fraction by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)
Total concentration of ALN-CIDEB in plasma
Total concentration of potential major metabolite(s) in plasma
Urinary recovery of ALN-CIDEB as a proportion of the dose
Urinary recovery of potential major metabolite(s) as a proportion of the dose
Show 3 moreShow less
Change in Aspartate Aminotransferase (AST)
Change in Alanine Aminotransferase (ALT)
Change in hepatic Cell death-Inducing DNA fragmentation factor alpha-like Effector B (CIDEB) messenger RiboNucleic Acid (mRNA) level

Arms and interventions

Part AExperimental

Randomized per the protocol

Part BExperimental

Randomized per the protocol

Drugs: ALN-CIDEB, Placebo

Sites

4 sites in 2 countries

United Kingdom 2, United States 2